Repligen (NASDAQ:RGEN) Price Target Raised to $208.00

Repligen (NASDAQ:RGEN) had its price objective boosted by investment analysts at HC Wainwright from $180.00 to $208.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 82.65% from the stock’s current price.

Several other brokerages have also issued reports on RGEN. Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. Barclays decreased their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. UBS Group dropped their price target on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, Wells Fargo & Company decreased their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $176.92.

Repligen Stock Performance

Shares of Repligen stock opened at $113.88 on Monday. The company has a quick ratio of 7.12, a current ratio of 8.37 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $102.96 and a 52 week high of $175.77. The firm’s 50 day moving average is $140.22 and its two-hundred day moving average is $146.90. The firm has a market capitalization of $6.41 billion, a P/E ratio of 133.98, a P/E/G ratio of 2.23 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. The business had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.44 EPS. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Research analysts forecast that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen in the third quarter valued at about $29,000. Bayforest Capital Ltd purchased a new position in Repligen during the fourth quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen in the fourth quarter valued at about $33,000. Los Angeles Capital Management LLC purchased a new stake in Repligen in the 4th quarter valued at approximately $36,000. Finally, CWM LLC increased its position in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 135 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.